Foundation Medicine, which develops diagnostic systems that assess genomic alterations in cancer cells and match patients with targeted therapies, announced terms for its IPO on Thursday. The Cambridge, MA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Foundation Medicine would command a fully diluted market value of $421 million.
Help employers find you! Check out all the jobs and post your resume.
